OakChart

Innoviva Inc

INVAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:12 AM ET

18.74-0.34 (-1.76%)
2026-11-11 16:13 CET
Market cap
1,356.23 USD m
Revenue, TTM
452.12 USD m
Net income, TTM
193.44 USD m
Free cash flow, TTM
182.51 USD m
EPS diluted, TTM
2.00
P/E
9.38
Compare

Price

INVA against its 20, 50 and 200-day averages
2050200miss
20.0022.0024.002.0M4.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INVAclose 18.7420-day 20.5350-day 20.79200-day 21.8918.74

25.5% under 25.15 on 26 Feb 2026. Last 15 sessions, 15.8% high to low

Profile

INVA
52-week range, 1% of the way up
18.7025.15

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

IndexRUT
Employees159
IPOOct 05, 2004
Beta0.38
ATR, 14d0.70
Rel volume0.36
Short float10.68%
Insider own1.28%
Inst own106.08%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.33B
Enterprise Value1.01B
Income193.44M
Sales452.12M
Book/sh15.90
Cash/sh8.30
Dividend Est.-
Dividend TTM-
Dividend Ex-DateSep 08, 2015
Dividend Gr. 3/5Y- -
Payout0.00%
Employees159
IPOOct 05, 2004

Ratios

P/E9.38
Forward P/E8.69
PEG-
P/S2.95
P/B1.18
P/C2.26
P/FCF7.30
EV/EBITDA4.80
EV/Sales2.24
Quick Ratio14.58
Current Ratio15.44
Debt/Eq0.24
LT Debt/Eq0.24
Option/ShortYes / Yes

Earnings

EPS (ttm)2.00
EPS next Y2.16
EPS next Q0.45
EPS this Y-65.03%
EPS next Y86.83%
EPS next 5Y-14.05%
EPS past 3/5Y- 10.35%
Sales past 3/5Y325.77% 3.93%
EPS Y/Y TTM34.41%
Sales Y/Y TTM12.38%
EPS Q/Q-194.79%
Sales Q/Q-1.51%
EarningsNov 04 AMC
EPS/Sales Surpr.-300.00% -7.97%

Ownership

Insider Own1.28%
Insider Trans0.00%
Inst Own106.08%
Inst Trans-2.51%
ROA13.04%
ROE18.02%
ROIC13.75%
Gross Margin72.20%
Oper. Margin37.63%
Profit Margin42.79%
SMA20-8.71%
SMA50-9.85%
SMA200-14.39%
Trades-

Technical

Shs Outstand71.54M
Shs Float70.17M
Short Float10.68%
Short Ratio9.05
Short Interest7.50M
52W High25.15 -25.45%
52W Low18.70 0.24%
Volatility5.94% 3.25%
ATR (14)0.70
RSI (14)29.33
Beta0.38
Rel Volume0.36
Avg Volume828.34K
Volume44,977

Performance

Perf Week-11.83%
Perf Month-9.62%
Perf Quarter-9.67%
Perf Half Y-19.00%
Perf YTD-6.23%
Perf Year-14.41%
Perf 3Y39.16%
Perf 5Y5.19%
Perf 10Y71.34%
Recom1.80
Target Price34.80
Prev Close19.08
Price18.74
Change %-1.76%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Sep 23, 2026ResumedOOppenheimerOutperform$35+86.7%
Feb 17, 2026InitiatedBBTIG ResearchBuy$35+86.7%
Sep 30, 2025InitiatedGGoldmanSell$17-9.3%
Aug 11, 2025InitiatedOOppenheimerOutperform$45+140.1%
Jul 14, 2025InitiatedHH.C. WainwrightBuy$40+113.4%
Jul 11, 2025InitiatedCCantor FitzgeraldOverweight$26+38.7%
Mar 07, 2025InitiatedBScotiabankSector Outperform$55+193.4%
Jun 18, 2024InitiatedCCantor FitzgeraldOverweight
Jul 20, 2022InitiatedGGoldmanNeutral$16-14.6%
Nov 20, 2017InitiatedDDeutsche BankHold$13-30.6%

Peers

Mkt cap
TickerCompanyMkt cap
LGNDLigand Pharmaceuticals Inc6.35B
RPRXRoyalty Pharma plc39.73B
HRMYHarmony Biosciences Holdings Inc1.97B
ADMAAdma Biologics Inc2.84B
MIRMMirum Pharmaceuticals Inc6.12B
PCRXPacira BioSciences Inc1.46B
GSKGSK Plc ADR100.06B
SPROSpero Therapeutics Inc59.40M
HRTXHeron Therapeutics Inc66.19M
EBSEmergent Biosolutions Inc311.57M

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
DFSVUS Small Cap Value Portfolio ETF Class Shares-
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
DFATU.S. Targeted Value Portfolio-ETF Class Shares-
VXFVanguard Extended Market Index ETFAUM: 30.47B
PJPInvesco Pharmaceuticals ETFAUM: 603.92M
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 206
  • Innoviva: Q3 Earnings Snapshot (Associated Press) -9.50%
  • Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress (Business Wire)
  • Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026 (Business Wire)
  • Oppenheimer Sees Massive Upside in 2 Stocks (GuruFocus.com)
  • Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
  • Loading…
  • Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO, ZEVTERA and NUZOLVENCE Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award (Business Wire)
  • Innoviva: Q2 Earnings Snapshot (Associated Press)
  • Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress (Business Wire)
  • Nortiva Bio Launches to Develop Long-Acting Oral Medicines (Business Wire)
  • Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddys for XACDURO in Select International Markets (Business Wire)
  • Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
  • Innoviva: Q1 Earnings Snapshot (Associated Press)
  • Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-1.0300.515-1.030106.12115.314
2026Q22026-08-05-1.1400.436-1.136119.59110.985
2026Q12026-05-062.2200.3902.21697.99101.575
2025Q42026-02-251.9400.5511.944114.61102.625
2025Q32025-11-051.0800.4601.082107.891.365
2025Q22025-08-060.7700.4990.773100.2892.043
2025Q12025-05-07-0.7400.294-0.74388.6382.671
2024Q42025-02-260.2600.3700.28391.8186.802
2024Q32024-11-060.0200.2650.01989.5176.912
2024Q22024-07-31-0.5500.235-0.55599.9074.692
2024Q12024-05-080.4600.1700.46277.5068.001
2023Q42024-02-290.7600.2300.76185.8475.521
2023Q32023-11-010.9800.2700.98567.2675.661
2023Q22023-08-020.0200.2600.02080.9967.921
2023Q12023-05-090.4200.2300.41976.3762.012
2022Q42023-02-28-0.9800.225-0.98165.8058.852

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.4301.7051.428261.02257.47
2020FY2.0202.1902.018336.79260.58
2021FY2.870-2.869391.87-
2022FY2.3703.715-1.077331.34337.53
2023FY2.2001.6702.202310.46300.14
2024FY0.3600.4250.362358.71353.7
2025FY3.3001.9013.300411.33399.31
2026FY-1.154--437.76
2027FY-2.156--475.35
2028FY-2.095--505.13
2029FY-2.000--570.9
2030FY-2.220--641.81

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-05513112.68106.58120.06
2026Q4S2026-11-04510118.4299.80141.3
2026Q4S2026-10-20510118.4299.80141.3
2026Q4S2026-09-21522118.4299.80141.3
2026Q4S2026-08-21412118.2199.80141.3
2026Q4S2026-08-19512118.0599.80141.3
2026Q4S2026-08-12512118.0599.78141.3
2026Q4S2026-08-06522118.0599.78141.3
2026Q4S2026-07-21510119.17112.34128.2
2026Q4S2026-05-29520119.17112.34128.2
2026Q4S2026-05-12510118.92112.34128.2
2026Q4S2026-05-07520118.92112.34128.2
2026Q4S2026-04-06411116.18101.1127.4
2026Q4S2026-02-26411116.17101.09127.4

Estimate history

EPS, annual1.1663.5331.4282.0182.869-1.0772.2020.3623.3011.9981
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0190.283-0.7430.7731.0821.9442.216-1.136-1.025
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual231.04274.827274.839350.617405.6895.508324.263372.511425.128452.12
Period201720182019202020212022202320242025TTM
Sales, quarterly92.96495.23892.088103.739111.256118.045101.45123.047109.576
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual101.896101.098101.288101.39269.56636.14563.30762.66574.63671.536
Period201720182019202020212022202320242025MRQ
Shares, quarterly62.60162.66562.77163.01174.76974.63673.80872.63771.536
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue452.12425.13372.51324.265.51405.69350.62274.84274.83
Cost of Goods Sold Incl. D&A125.67117.6176.4578.340.8913.83---
Gross Profit326.44307.52296.06245.924.62391.86---
Selling, General and Administrative Excl. Other156.29143.77129.19132.0341.5613.4513.9511.5117.00
Research and Development20.2030.6013.6533.9235.020.581.790.000.00
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income170.15163.75166.87113.89-36.95378.40322.82249.46243.95
Interest Expense19.6916.7022.2119.160.0019.0718.3318.6623.95
Unusual Expense-44.57-161.59123.41-88.520.00-87.73-48.583.3211.45
Net Income Before Taxes223.97326.8637.39194.10-36.92445.28354.25232.90210.25
Income Taxes30.5355.7014.0014.380.0076.4460.4341.90-196.07
Consolidated Net Income193.44271.1723.39179.72-36.92368.84293.81190.99406.33
Net Income From Continuing Operations193.44271.1723.39179.72-36.92265.85224.40157.29395.06
Net Income193.44271.1723.39179.72-36.92265.85224.40157.29395.06
EPS (Recurring)2.291.971.531.49-1.082.221.721.453.60
EPS (Basic, Before Extraordinaries)2.554.020.372.75-1.083.242.211.553.92
EPS (Diluted)2.003.300.362.20-1.082.872.021.433.53
EBITDA210.70203.97206.72149.59-36.05392.24336.66263.33257.82
Non-Operating Income (Expense)28.9418.2216.1410.850.03-1.791.185.411.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense10.657.475.044.613.101.471.241.502.55
Price To Earnings Ratio9.559.5525.2336.314.226.256.149.904.94
Price To Sales Ratio3.383.993.464.3082.504.014.015.847.20
Gross Margin72.2072.3379.4875.8483.8196.59---
Operating Margin37.6338.5244.8035.12-670.7793.2792.0790.7788.77
Net Margin42.7963.786.2855.42-670.2465.5364.0057.23143.75
Shares Outstanding71.5474.6462.6663.3136.1469.57101.39101.29101.10
Market Capitalization1,356.231,356.231,086.131,027.95924.631,198.741,256.251,434.111,763.15

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue109.58123.05101.45118.05111.26103.7492.0995.24
Cost of Goods Sold Incl. D&A25.1932.4325.6242.4335.7520.6218.8017.16
Gross Profit84.3890.6275.8375.6175.5183.1173.2878.08
Selling, General and Administrative Excl. Other42.2339.7637.6836.6240.9334.3631.8634.94
Research and Development5.215.195.244.5513.677.984.403.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income42.1550.8538.1538.9934.5848.7541.4343.14
Interest Expense5.475.475.443.314.014.664.714.75
Unusual Expense139.49160.99-191.22-153.82-62.26-24.3678.8519.59
Net Income Before Taxes-97.61-108.02234.56195.0497.8272.60-38.5924.69
Income Taxes-23.72-24.6047.9730.887.918.918.004.36
Consolidated Net Income-73.89-83.42186.59164.1589.9163.69-46.5820.33
Net Income From Continuing Operations-73.89-83.42186.59164.1589.9163.69-46.5820.33
Net Income-73.89-83.42186.59164.1589.9163.69-46.5820.33
EPS (Recurring)0.330.400.640.680.570.570.140.45
EPS (Basic, Before Extraordinaries)-1.03-1.142.522.191.301.01-0.740.32
EPS (Diluted)-1.03-1.142.221.941.080.77-0.740.28
EBITDA52.3961.0148.2049.1144.6858.7951.3953.13
Non-Operating Income (Expense)5.207.5810.625.544.994.153.545.89
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.903.752.031.981.881.911.701.32
Price To Earnings Ratio9.553.787.6314.3455.00-86.6625.23
Price To Sales Ratio3.383.674.554.013.854.422.963.92
Gross Margin77.0173.6474.7564.0567.8780.1279.5881.98
Operating Margin38.4741.3337.6133.0331.0846.9944.9945.30
Net Margin-67.43-67.80183.93139.0680.8161.39-50.5921.35
Shares Outstanding71.5472.6473.8174.6474.7763.0162.7762.66
Market Capitalization1,356.231,676.201,725.921,494.631,150.131,261.151,136.311,086.13

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments566.67412.50193.5114.85201.53246.49350.85114.91129.07
Short Term Receivables93.3286.3784.088.53110.7193.9379.4383.2970.54
Inventories39.1733.7340.740.000.000.000.000.000.00
Other Current Assets28.3621.7225.893.661.441.640.960.850.75
Total Current Assets727.51554.31344.2227.05313.67342.06431.23199.04200.37
Net Property, Plant & Equipment12.482.973.0246.650.010.030.030.160.21
Total Investments and Advances598.22393.96560.985.96483.85438.260.000.000.00
Intangible Assets200.06226.34248.2413.750.000.000.000.000.00
Deferred Tax Assets0.0046.48-0.0017.3393.76154.17196.05-
Other Assets96.88111.4487.052.43111.54125.47139.39152.94166.76
Total Assets1,635.161,335.481,243.5195.83926.39999.57724.83548.19367.34
Short Term Debt Incl. Current Port. of LT Debt0.42193.601.2117.010.000.000.000.0025.00
Accounts Payable4.972.136.721.680.030.070.010.010.60
Income Tax Payable0.27-0.000.15-----
Other Current Liabilities44.0440.3530.216.185.786.045.365.699.14
Total Current Liabilities49.70236.0838.1324.875.816.115.375.7034.74
Long Term Debt268.60257.50447.8731.80394.65385.52377.22383.36574.36
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities31.7934.420.563.08-----
Other Liabilities112.24116.3281.990.000.000.110.120.090.94
Total Liabilities462.32644.33568.5559.75400.46391.73382.71389.14610.04
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,172.84691.16674.9636.08414.74539.91313.50153.58-242.86
Total Shareholders Equity1,172.84691.16674.9636.08414.74539.91313.50153.58-242.86
Accumulated Minority Interest0.000.000.000.00111.1967.9228.625.470.15
Total Equity1,172.84691.16674.9636.08525.93607.84342.12159.05-242.71
Total Liabilities & Stockholders Equity1,635.161,335.481,243.5195.83926.39999.57724.83548.19367.34
Book Value Per Share15.7111.0310.661.005.965.333.101.52-2.38
Tangible Book Value Per Share13.037.426.740.625.965.323.101.52-2.38
Full-Time Employees159127112101556612
Price to Book Ratio1.201.621.651.442.892.334.5811.49-6.87
Return on Assets18.261.8114.52-7.2227.6126.0324.7186.3035.95
Return on Equity29.093.4228.97-16.3855.7052.5967.35--
Return on Invested Capital18.812.4716.01-54.3832.8524.2522.7773.5840.47
Quick Ratio13.852.217.961.0954.0255.9880.2934.925.77
Current Ratio14.642.359.031.0954.0255.9880.2934.925.77

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income193.44271.1723.39179.72-36.92368.84293.81190.99406.33
Depreciation40.5540.2339.8535.700.8913.8313.8413.8713.87
Other Funds (Non Cash)-23.33-134.15145.00-53.972.60-78.42-40.647.6216.14
Funds from Operations225.56221.09195.62165.85-33.42380.69327.44254.36240.29
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-42.09-24.16-6.93-24.790.44-16.87-14.323.10-16.76
Income Taxes Payable-36.474.0641.481.7310.03----
Cash from Operating Activities183.47196.93188.69141.06-32.98363.81313.11257.46223.53
Capital Expenditures-0.95-1.13-4.27-0.41-2.210.00-0.01-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.220.010.100.000.000.000.000.000.00
Purchase or Sale of Investments0.6850.98-59.62-66.350.0043.72-314.92-17.993.52
Purchase of Investments-102.45-78.40-135.37-138.850.00-257.25-400.92-231.91-71.86
Sale Or Maturity of Investments103.13129.3875.7672.500.00300.9786.00213.9275.38
Other Uses0.00-9.370.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.0540.50-63.79-66.76-2.2143.72-314.94-18.003.52
Cash Dividends Paid0.000.000.000.000.000.000.00-0.01-0.08
Change in Capital Stock-78.538.58-13.45-75.6444.39-393.040.340.54-1.93
Repurchase of Common Pref Stock-82.26-4.67-14.92-75.810.00-394.21-0.09-0.09-3.07
Sale of Common Pref Stock3.7213.251.470.1744.391.170.440.631.14
Proceedsfrom Stock Options3.722.551.470.1744.391.170.440.631.14
Issuance or Reduction of Debt, Net0.00-0.030.00-96.200.000.000.00-13.75-230.00
Change in Long Term Debt0.00-0.030.00-96.200.000.000.00-13.75-230.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.00-0.030.00-96.200.000.000.00-13.75-230.00
Net Financing Active Other Cash Flow0.000.000.000.000.12-59.46-30.13-10.55-5.96
Other Financing Activities Uses0.000.000.000.000.00-59.46-30.47-10.55-5.96
Cash from Financing Activities-78.538.55-13.45-171.8444.52-452.50-29.79-23.78-237.97
Net Change in Cash104.88245.98111.45-97.549.32-44.96-31.61215.68-10.92
Free Cash Flow182.51195.80188.42140.65-35.19363.81313.10257.45223.53
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow8.388.656.839.916.264.474.496.248.86
Deferred Taxes & Investment Tax Credit-43.85-12.624.400.0076.4360.4241.88-196.05

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments590.06579.06611.93566.67533.10497.73
Short Term Receivables102.13110.6292.6393.3293.5288.26
Inventories42.8438.9738.8439.1738.3649.00
Other Current Assets37.2324.7329.2228.3619.5916.79
Total Current Assets772.25753.37772.62727.51684.57651.78
Net Property, Plant & Equipment12.1412.5112.7912.482.932.21
Total Investments and Advances526.79660.85764.45598.22426.37349.11
Intangible Assets180.18186.88193.51200.06206.70213.32
Deferred Tax Assets---0.007.9812.93
Other Assets46.5689.1293.2196.88100.55104.23
Total Assets1,537.931,702.731,836.591,635.161,429.111,333.57
Short Term Debt Incl. Current Port. of LT Debt0.760.710.650.420.68200.28
Accounts Payable6.504.026.524.976.245.38
Income Tax Payable0.000.000.000.27--
Other Current Liabilities42.7742.3429.3944.0441.5540.90
Total Current Liabilities50.0347.0636.5649.7048.47246.56
Long Term Debt269.11268.94326.08268.60258.28317.04
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities6.9136.7472.8331.79--
Other Liabilities74.35116.7259.46112.24112.4055.15
Total Liabilities400.41469.46494.93462.32419.15618.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,137.521,233.261,341.651,172.841,009.95714.82
Total Shareholders Equity1,137.521,233.261,341.651,172.841,009.95714.82
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,137.521,233.261,341.651,172.841,009.95714.82
Total Liabilities & Stockholders Equity1,537.931,702.731,836.591,635.161,429.111,333.57
Book Value Per Share15.9016.9818.1815.7113.5111.34
Tangible Book Value Per Share13.3814.4115.5613.0310.747.96
Full-Time Employees---159--
Price to Book Ratio1.201.251.481.481.611.95
Return on Assets13.0423.5332.6318.269.573.02
Return on Equity18.0236.6850.7229.0915.175.60
Return on Invested Capital-5.25-5.5511.1911.397.096.17
Quick Ratio14.5815.1820.0713.8513.332.44
Current Ratio15.4416.0121.1314.6414.122.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-73.89-83.42186.59164.1589.9163.69
Depreciation10.2310.1510.0410.1210.1110.04
Other Funds (Non Cash)144.39167.13-186.12-148.73-46.59-21.40
Funds from Operations50.9157.7751.5565.3258.3751.69
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-9.21-5.80-16.27-10.80-8.64-7.62
Income Taxes Payable-40.531.591.061.410.73-0.46
Cash from Operating Activities41.7051.9735.2854.5149.7344.07
Capital Expenditures-0.02-0.43-0.49-0.01-1.120.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.030.180.000.010.000.00
Purchase or Sale of Investments-5.43-55.0237.5023.6328.9033.12
Purchase of Investments-5.43-55.84-12.46-28.73-15.0019.94
Sale Or Maturity of Investments0.000.8249.9652.3643.9013.18
Other Uses0.000.000.000.00-9.370.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-5.43-55.2637.0123.6418.4133.12
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-25.26-29.41-20.15-3.7210.871.25
Repurchase of Common Pref Stock-26.13-31.16-20.41-4.56-0.03-0.02
Sale of Common Pref Stock0.871.760.260.8410.891.27
Proceedsfrom Stock Options0.871.760.260.840.191.27
Issuance or Reduction of Debt, Net0.000.000.000.00-0.030.00
Change in Long Term Debt0.000.000.000.00-0.030.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00-0.030.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-25.26-29.41-20.15-3.7210.841.25
Net Change in Cash11.01-32.7052.1474.4378.9878.44
Free Cash Flow41.6751.5434.7954.5048.6144.07
Price to Free Cash Flow8.388.8010.868.707.738.47

Revenue breakdown

Consolidation, Policy2025: 610.00K
GIAPREZA2024: 55.04M 2025: 73.61M
License And Other2024: 19.49M 2025: 2.72M
Royalty2024: 241.73M 2025: 236.48M
XACDURO2024: 21.07M 2025: 74.39M
XERAVA2024: 21.39M 2025: 23.52M
United States2024: 358.71M 2025: 411.33M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.68%7.5M70.2M772.93K
2026-10-1510.19%7.3M71.3M776.58K
2026-09-309.60%6.8M71.3M813.14K
2026-09-1510.02%7.1M71.3M767.92K
2026-08-319.73%6.9M71.3M787.76K
2026-08-149.62%6.9M71.3M849.80K
2026-07-319.66%6.9M71.3M831.70K
2026-07-159.63%7.0M72.9M826.99K
2026-06-309.12%6.6M72.9M772.06K
2026-06-159.06%6.6M72.8M769.65K
2026-05-298.04%5.9M72.9M726.21K
2026-05-158.77%6.4M72.9M713.01K
2026-04-308.62%6.3M72.9M755.54K
2026-04-159.14%6.7M73.6M763.30K
2026-03-318.94%6.5M73.2M775.52K
2026-03-139.31%6.8M73.2M803.55K
2026-02-279.10%6.7M73.2M820.20K
2026-02-139.09%6.7M73.9M817.59K
2026-01-308.28%6.1M73.9M833.72K
2026-01-158.11%6.0M73.9M868.06K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.504.409.000.005.5770.000.000.866-0.1060.006
call15.003.405.800.003.4130.000.000.808-0.0920.008
call17.500.654.900.003.7080.000.000.662-0.1010.011
call20.000.000.600.270.89721.000.000.482-0.1020.012
call22.500.000.550.201.2921850.000.252-0.0660.010
call25.000.001.000.051.8301010.000.205-0.0850.008
call30.000.000.750.002.5150.000.000.165-0.1020.007
put12.500.001.000.001.7930.000.00-0.056-0.0320.004
put15.000.000.750.002.0260.000.00-0.192-0.0900.008
put17.500.000.950.004.8680.000.00-0.308-0.2650.011
put20.000.004.900.703.5241200.00-0.518-0.1000.012
put22.501.204.500.001.7320.000.00-0.753-0.0700.009
put25.003.507.800.002.9620.000.00-0.795-0.0830.008
put30.008.7013.500.004.3790.000.00-0.835-0.0980.007

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-27SCHEDULE 13G/ASEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13GSEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-203Initial statement of beneficial ownership of securities2026-05-18SEC
2026-05-188-KCurrent report2026-05-12SEC
2026-05-13SCHEDULE 13D/ASEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-29SCHEDULE 13GSEC
2026-03-2710-K/A2025-12-31SEC
2026-03-27SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.15.66%
DIMENSIONAL FUND ADVISORS LP6.25%
VANGUARD PORTFOLIO MANAGEMENT LLC5.72%
RENAISSANCE TECHNOLOGIES LLC5.47%
STATE STREET CORP4.43%
VANGUARD CAPITAL MANAGEMENT LLC4.28%
MILLENNIUM MANAGEMENT LLC3.44%
GEODE CAPITAL MANAGEMENT, LLC2.85%
SYSTEMATIC FINANCIAL MANAGEMENT LP2.74%
Sarissa Capital Management LP2.56%

Funds

Fund% owned
iShares Convertible Bond ETF7.01%
iShares Core S&P Small-Cap ETF5.72%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF2.63%
VANGUARD SMALL-CAP INDEX FUND2.18%
VANGUARD SMALL-CAP VALUE INDEX FUND1.38%
U.S. SMALL CAP VALUE PORTFOLIO1.37%
Avantis U.S. Small Cap Value ETF1.17%
Fidelity Small Cap Index Fund1.12%
VANGUARD EXTENDED MARKET INDEX FUND1.09%

OakChart. INVA. Cached 15 minutes.

Some panels did not load: insider.